CN113491765A - Composition containing propolis and natural extract for female cleanser and preparation method thereof - Google Patents
Composition containing propolis and natural extract for female cleanser and preparation method thereof Download PDFInfo
- Publication number
- CN113491765A CN113491765A CN202010200440.7A CN202010200440A CN113491765A CN 113491765 A CN113491765 A CN 113491765A CN 202010200440 A CN202010200440 A CN 202010200440A CN 113491765 A CN113491765 A CN 113491765A
- Authority
- CN
- China
- Prior art keywords
- composition
- extract
- propolis
- natural
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 239000000284 extract Substances 0.000 title claims abstract description 66
- 241000241413 Propolis Species 0.000 title claims abstract description 52
- 229940069949 propolis Drugs 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 25
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 30
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 17
- 244000144927 Aloe barbadensis Species 0.000 claims abstract description 16
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 16
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 15
- 229960000458 allantoin Drugs 0.000 claims abstract description 15
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 15
- 239000009429 Ginkgo biloba extract Substances 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 206010046914 Vaginal infection Diseases 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims abstract description 13
- 229940068052 ginkgo biloba extract Drugs 0.000 claims abstract description 13
- 229930003231 vitamin Natural products 0.000 claims abstract description 13
- 235000013343 vitamin Nutrition 0.000 claims abstract description 13
- 239000011782 vitamin Substances 0.000 claims abstract description 13
- 229940088594 vitamin Drugs 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 12
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 12
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 11
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 11
- 201000008100 Vaginitis Diseases 0.000 claims abstract description 11
- 239000007884 disintegrant Substances 0.000 claims abstract description 11
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims abstract description 7
- 206010051873 Vaginal relaxation Diseases 0.000 claims abstract description 6
- 210000001215 vagina Anatomy 0.000 claims description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 229960000913 crospovidone Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 229940044977 vaginal tablet Drugs 0.000 claims description 5
- 239000000003 vaginal tablet Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229930003268 Vitamin C Natural products 0.000 claims description 4
- 229940032147 starch Drugs 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000019154 vitamin C Nutrition 0.000 claims description 4
- 239000011718 vitamin C Substances 0.000 claims description 4
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- 229940050410 gluconate Drugs 0.000 claims description 3
- 229940049654 glyceryl behenate Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229960001375 lactose Drugs 0.000 claims description 3
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229950008882 polysorbate Drugs 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 3
- 229940080313 sodium starch Drugs 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 239000011716 vitamin B2 Substances 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 210000003491 skin Anatomy 0.000 description 18
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 14
- 229920001661 Chitosan Polymers 0.000 description 13
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 230000003020 moisturizing effect Effects 0.000 description 13
- 208000003251 Pruritus Diseases 0.000 description 12
- 241001480003 Chaetothyriales Species 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 206010040880 Skin irritation Diseases 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 230000036556 skin irritation Effects 0.000 description 9
- 231100000475 skin irritation Toxicity 0.000 description 9
- 210000002229 urogenital system Anatomy 0.000 description 8
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 7
- 230000007794 irritation Effects 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 7
- 239000004310 lactic acid Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 241000382455 Angelica sinensis Species 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001603 reducing effect Effects 0.000 description 5
- 230000037394 skin elasticity Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241001116389 Aloe Species 0.000 description 4
- 244000146462 Centella asiatica Species 0.000 description 4
- 235000004032 Centella asiatica Nutrition 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 description 3
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 description 3
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 3
- 229940022757 asiaticoside Drugs 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000036560 skin regeneration Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 210000003905 vulva Anatomy 0.000 description 3
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 2
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010046814 Uterine prolapse Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- AGABNGOXUSXQDD-XKGFZTIGSA-N [(3s)-2,2-dimethyl-8-oxo-3,4-dihydropyrano[3,2-g]chromen-3-yl] (z)-2-methylbut-2-enoate Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C(\C)=C/C)C(C)(C)OC1=C2 AGABNGOXUSXQDD-XKGFZTIGSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 2
- AGABNGOXUSXQDD-UHFFFAOYSA-N decursinol angelate Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C(C)=CC)C(C)(C)OC1=C2 AGABNGOXUSXQDD-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 244000039328 opportunistic pathogen Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000242092 Aloe saponaria Species 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000223678 Aureobasidium pullulans Species 0.000 description 1
- 208000022844 Bacterial Sexually Transmitted disease Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010061041 Chlamydial infection Diseases 0.000 description 1
- 241000498849 Chlamydiales Species 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241001091575 Echeveria Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- BNMGUJRJUUDLHW-HCZMHFOYSA-N Madecassoside Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(C[C@@H](O)[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O BNMGUJRJUUDLHW-HCZMHFOYSA-N 0.000 description 1
- BNMGUJRJUUDLHW-HLUHVYOBSA-N Madecassoside Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5[C@H](O)C[C@@]34C)[C@@H]2[C@H]1C)C(=O)O[C@@H]6O[C@H](CO[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@@H](O)[C@H](O)[C@H]6O BNMGUJRJUUDLHW-HLUHVYOBSA-N 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000206755 Palmaria Species 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 241000517305 Pthiridae Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 240000005382 Saccharum spontaneum Species 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000003300 Uterine Retroversion Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046940 Vaginal prolapse Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 206010066416 Vulvovaginal human papilloma virus infection Diseases 0.000 description 1
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical group 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 201000000902 chlamydia Diseases 0.000 description 1
- 208000012538 chlamydia trachomatis infectious disease Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 208000028454 lice infestation Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 1
- 229940011656 madecassic acid Drugs 0.000 description 1
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 1
- 229940090813 madecassoside Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000000260 male genitalia Anatomy 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046811 uterine polyp Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to a composition containing propolis and natural extracts for a female cleanser and a preparation method thereof. The composition for a female cleanser comprises: propolis, collagen peptide, a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract and mixtures thereof, an excipient, a water-soluble vitamin, a disintegrant and a lubricant show excellent effects in preventing or treating vaginal-related diseases, and more particularly, to a composition for non-oral administration for preventing or treating vaginal relaxation, vaginal dryness or vaginitis.
Description
Technical Field
The invention relates to a composition containing propolis and natural extracts for a female cleanser and a preparation method thereof. More particularly, it relates to a composition for a female cleanser containing propolis and natural extracts as main ingredients for preventing or treating vaginal-related diseases and a method for preparing the same.
Background
Female genitourinary organs consist of ovaries, oviducts, uteri, cervix, vagina and vulva, and female genitourinary system diseases comprise pelvic inflammation, endometriosis, ovarian cysts, polycystic ovarian syndrome, ovarian cancer, uterine myoma, uterine polyps, retroflexed uterus, uterine and vaginal prolapse, uterine cancer, choriocarcinoma, cervical erosion, cervical dysplasia, cervical cancer, vulval vaginitis, vaginal mycosis, bacterial vaginitis, badionitis, vulva and vaginal cancer, venereal diseases (gonorrhea, chlamydial pelvic inflammation, syphilis, trichomoniasis, pudendum herpes, vulval warts, pubic lice) and the like.
The weakly acidic lactobacillus capable of keeping the pH value of the urogenital system at 4.5-6.5 exists in the female urogenital system, plays a role in inhibiting the propagation of harmful bacteria, but can be used for eliminating physical injury and hormone imbalance, bacterial diseases or venereal diseases and the like caused by unclean urogenital system environment and sexual relations, and is easy to cause female urogenital system related diseases. That is, according to the functional characteristics of the female urogenital system structure, the vagina and the vulva are directly exposed to the external environment, and various conditions for culturing bacterial colonies, such as the male genitalia, temperature, humidity, etc., are provided, resulting in bacterial infection and bacterial vaginosis.
The vagina of a normal female typically contains about 10 per milliliter of vaginal material4The above lactic acid bacterium (Lactobacillus spp.). Under normal conditions, the vaginal flora provides a weakly acidic environment, contributing to the protection against the invasion of pathogenic microorganisms.
However, under these normal conditions, the vaginal flora, i.e., vaginal balance, is easily disrupted by various external factors that ultimately lead to vaginal infections. Vaginal infections are clinical syndromes, and bacterial vaginosis, candidal vaginitis, trichomonas vaginitis and the like are mainly reported, wherein the most common vaginitis is bacterial vaginitis.
It is reported that the bacterial vaginal disease is mainly caused by an increase in the number of anaerobic organisms accompanied by a decrease in lactic acid bacteria in the vagina, and in addition, may be caused by bacterial or viral infection, administration of antibiotics or contraceptives, excessive use of vaginal cleansers, and the like. The decrease in the number of lactic acid bacteria in the vagina decreases competition for nutrition, and the decrease in the amount of lactic acid present leads to an increase in pH, causing the proliferation of opportunistic pathogens (opportunistic pathogens) that are normally inhibited in their growth in the vagina, leading to morbidity.
The pH of the normal vagina is 4.5 to 5.1. The reason why the inside of the vagina is acidic is that intravaginal microorganisms and vaginal epithelial cells produce lactic acid (lactic acid) using glycogen (glycogen) and glucose (glucose). Lactic acid bacteria inhabiting the vagina produce lactic acid (lactic acid) to maintain pH, thereby inhibiting the proliferation of harmful bacteria, and playing a beneficial role.
Bacterial vaginosis is the most common cause of inflammation in the vagina and whether infection is through sexual relations is not clear. However, bacterial vaginitis has been reported to be associated with a disease caused by venereal infection such as gonorrhea and chlamydial infection. The reproduction degree of lactic acid bacteria in normal bacteria in the vagina is reduced, so that anaerobic bacteria in the normal bacteria in the vagina are excessively reproduced, and bacterial vaginitis is generated. Representative symptoms are increased vaginal secretions and colored and fishy smelling. The cause of the characteristic odor is aromatic amines produced by the over-propagating bacteria.
In order to prevent the female urogenital system related diseases, the ancestors treat vaginitis by a hip bath method of cooling boiled water boiled by adding radish leaves or wormwood since ancient times, and western females wash the lower bodies by adding water of rose, lavender, bergamot and the like, but the method has the defect of complicated use each time.
Therefore, there is a need for the development of a feminine cleanser or vaginal cleanser which is effective in preventing diseases associated with the female urogenital system, has low irritativeness, can be easily used, has low irritativeness as compared with soap and bath lotion which are generally used, contains natural functional components, and can provide a healthier environment when used.
Documents of the prior art
Patent document
Patent document 1: KR10-2014-0092635A1
Disclosure of Invention
The invention aims to provide a female cleanser composition containing propolis and natural extracts, which is effective for preventing or treating vagina-related diseases.
Another object of the present invention is to provide a non-oral composition comprising propolis and natural extracts for preventing or treating vaginal-related diseases.
In order to achieve the above object, a composition for a female cleanser containing propolis and a natural extract according to an embodiment of the present invention may include: propolis, collagen peptide, a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract and mixtures thereof, an excipient, a water-soluble vitamin, a disintegrant and a lubricant.
The propolis and the natural extract may be included at a weight ratio of 1:1 to 1: 5.
The water-soluble vitamin is selected from vitamin C and vitamin B1Vitamin B2Nicotinic acid, vitamin B6Vitamin B12Folic acid and biotin.
The excipient may be selected from the group consisting of silicified microcrystalline cellulose, starch, microcrystalline cellulose, mannitol, lactose, low substituted hydroxypropyl cellulose, sucralose, and mixtures thereof.
The disintegrant may be selected from the group consisting of crospovidone, sodium starch gluconate, croscarmellose sodium, polysorbate, sodium lauryl sulfate, and mixtures thereof.
The lubricant may be selected from the group consisting of magnesium stearate, light anhydrous silicic acid, talc, glyceryl behenate and mixtures thereof.
The composition is used for preventing or treating vagina-related diseases, such as vaginal relaxation, vaginal dryness or vaginitis.
The composition is a cleaning composition or a vaginal tablet.
The composition for a female cleanser containing propolis and a natural extract according to another embodiment of the present invention is prepared by the steps of: 1, pulverizing propolis, collagen peptide, and a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract, and a mixture thereof to prepare a pulverized material; a 2 nd step of putting the pulverized material into a 20 to 50 mesh sieve to sieve it to prepare a first mixture; step 3, putting the excipient, the water-soluble vitamin, the disintegrant and the lubricant into a sieve with 20 to 50 meshes to sieve so as to prepare a second mixture; a 4 th step of adding the second mixture to the first mixture and mixing to prepare a third mixture; and 5, adding a lubricant into the third mixture obtained in the 4 step, mixing and tabletting.
The first mixture of step 1 may include propolis and a natural extract in a weight ratio of 1:1 to 1: 5.
The present invention will be described in further detail below.
The composition for a female cleanser containing propolis and natural extract according to an embodiment of the present invention may include propolis, collagen peptide, natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract and a mixture thereof, excipient, water-soluble vitamin, disintegrant and lubricant.
The Propolis (Propolis) is a mixture of resins collected by bees from plants such as tree buds or sap, and is a natural antibacterial substance. Has antibacterial, immunity enhancing, cell activating and cell regenerating, antiallergic, gene damage preventing, blood vessel strengthening, antioxidant, and anticancer effects. In addition, propolis also has effect of regulating symptoms.
Allantoin (alantoin) is a natural extract extracted from malt, comfrey root, oak, tobacco seed, beet, etc. Has the functions of promoting the regeneration of healthy skin cells, such as directly or indirectly activating cell activities, and reconstructing undamaged granulation tissues. Has no toxicity and irritation, so that the record is recorded on FDA, and has the advantage of exerting the effect even at low concentration.
The Aloe Vera (Aloe Vera) is a representative Aloe species used in commerce or medicine, and it is usually planted for more than 3 years before the properties of the Aloe Vera are prominent. However, since it is a tropical crop, it requires relatively much cost for planting in korea, and the processed product imported from abroad has a problem of unstable quality due to uneven condition of the crop and unbalanced supply and demand. In addition, aloe vera is used by removing toxic bark from leaves and separating only the inner gel, which is a complicated process in the actual production steps of aloe-related products. In contrast, aloe saponaria is a mild herb of aloe used as fresh leaves, which may be used with the skin, but belongs to a small plant among the plants to which aloe belongs.
The folium Ginkgo (ginkgo biloba) refers to the leaves of the conventional ginkgo tree, and has the effects of improving the blood vessel function, resisting cancer, improving the functions of capillary vessels and veins, resisting aging and calming the skin.
The angelica has been known to have various pharmacological effects, and representative effects are treatment of anemia, tranquilization, analgesic effect, tonic, treatment of dysmenorrhea, treatment of climacteric syndrome, treatment of abdominal pain, treatment of wounds, treatment of arthritis, and treatment of diabetic hypertension. Many coumarins are known to exist in angelica sinensis, and decursin (decursin) and decursinol angelate (decursinolangelate) are typical and contained in large amounts, which has been reported since long ago (1967), and dihydropyranocoumarin (dihydropyranocoumarin) series substances have recently been reported to have anticancer effects.
The centella asiatica (centella asiatica extract) originates in tropical regions of the indian ocean, is a plant that grows completely naturally at an altitude of 600 meters in the shade, and is also called centella asiatica (gotu kola), echeveria indica (indiannenywok) or palmaria palmifolia (tiger grass). This centella asiatica contains asiaticoside (asiaticoside), asiaticoside (madecassoside), asiatic acid (asiatic acid) and madecassic acid components called triterpenes (saponins), which are known to regulate and promote the synthesis of collagen in the human body, strengthen blood vessels to promote blood circulation, and contribute to memory improvement.
The natural extract refers to an extract that can be extracted by a person skilled in the art in a conventional extraction method, and the extract may be in a powder form, without being limited to the example.
The propolis and the natural extract are contained in a weight ratio of 1:1 to 1:5, preferably 1:3 to 1:5, but not limited to the examples. The propolis is contained for antibacterial, anti-inflammatory and antioxidant effects, and the natural extract is contained for relieving skin problems, moisturizing, skin flexibility, skin elasticity, skin regeneration, improving blood circulation, calming sensitive skin, etc.
That is, by including propolis in a composition for a female cleanser, antibacterial, anti-inflammatory and antioxidant effects for preventing or treating vagina-related diseases can be exhibited, but may thereby cause a problem of irritation to the skin, and the present invention will solve such a problem by further including a natural extract.
However, in this case, when the propolis and the natural extract are contained at a ratio of less than 1:1, that is, when the content of the natural extract is less with respect to the weight of the propolis, there is a problem of skin irritation due to the propolis, and when it exceeds 1:5, that is, when the content of the natural extract is more with respect to the weight of the propolis, the effect of preventing or treating vaginal-related diseases may be reduced by the weak anti-inflammatory, antibacterial and antioxidant effects of the propolis.
The natural extract is selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica sinensis extract, centella asiatica extract and mixtures thereof, and more particularly, may include allantoin, aloe vera, ginkgo biloba extract, angelica sinensis extract and centella asiatica extract.
Preferably, the composition for a female cleanser may further include saccharomyces cerevisiae and chitosan in addition to the natural extract.
It is known that the black yeast (Aureobasidium pullulans) is excellent in moisturizing, elasticity, and allergic skin itching, and the chitosan is effective in discharge of heavy metals and fine dust, excellent in antibacterial effect, and enhancing moisturizing effect.
Therefore, the black yeast and chitosan are further included in the composition for a female cleanser, and can play a role in moisturizing, skin elasticity and excellent antibacterial effect.
The water-soluble vitamin is selected from vitamin C and vitamin B1Vitamin B2Nicotinic acid, vitamin B6Vitamin B12Folic acid and biotin, preferably vitamin C, i.e. characterized by the inclusion of ascorbic acid, but not limited to examples.
The water-soluble vitamin preferably contains ascorbic acid in order to maintain the pH in the vagina at a weak acid for an anti-inflammatory effect. In general, sodium salts, lactic acid buffer solutions, and the like are used in compositions for feminine cleansing in order to maintain the pH in the vagina at a weakly acidic level. This is an ingredient added to keep the pH in the vagina weakly acidic, but the ascorbic acid in the present invention can exhibit the effects of antioxidant effect, growth and recovery of skin tissue, prevention of carcinogen generation, and the like while maintaining the weakly acidic environment in the vagina.
The excipient is selected from the group consisting of silicified microcrystalline cellulose, starch, microcrystalline cellulose, mannitol, lactose, low-substituted hydroxypropyl cellulose, sucralose, and a mixture thereof, and specifically may comprise silicified microcrystalline cellulose
Starch (Starch1500), microcrystalline cellulose (microcrystalline cellulose PH102), and mannitol (mannitol 160C), but is not limited to the examples.
The disintegrant may be selected from the group consisting of crospovidone, sodium starch gluconate, croscarmellose sodium, polysorbate, sodium lauryl sulfate, and a mixture thereof, and more specifically, crospovidone (crospovidone CL-SF), but is not limited to the examples.
The lubricant may be selected from the group consisting of magnesium stearate, light anhydrous silicic acid, talc, glyceryl behenate and mixtures thereof, more specifically magnesium stearate, but is not limited to the examples.
A composition for a feminine cleanser according to one embodiment of the present invention may include: 0.1 to 1.5% by weight of collagen peptide, 0.1 to 1.5% by weight of allantoin, 0.1 to 1.5% by weight of aloe vera, 0.1 to 1.5% by weight of ginkgo biloba extract, 0.1 to 1.5% by weight of angelica sinensis extract, 0.1 to 1.5% by weight of centella asiatica extract, 0.1 to 1.5% by weight of chitosan, 0.1 to 1.5% by weight of black yeast, 0.2 to 3.0% by weight of propolis, 15 to 30% by weight of silicified microcrystalline cellulose, 15 to 30% by weight of starch, 10 to 20% by weight of microcrystalline cellulose, 20 to 40% by weight of mannitol, 0.5 to 5% by weight of water-soluble vitamin, 1 to 10% by weight of crospovidone, and 0.5 to 5% by weight of magnesium stearate.
The composition for female cleanser may have weak antibacterial, anti-inflammatory and antioxidant effects when it contains less than 0.2 wt% of propolis, and may have skin rash and dyspnea when it exceeds 3.0 wt%.
When the collagen peptide is contained in an amount of less than 0.1 wt% based on the total weight, there is a problem that the effect of improving elasticity and skin regeneration is weak, and when the collagen peptide is contained in an amount of more than 1.5 wt%, acne and allergic reaction are caused.
When the allantoin is contained in an amount of less than 0.1 wt% relative to the total weight, the effects of alleviating skin problems, moisturizing and skin flexibility are weak, and when it exceeds 1.5 wt%, the skin may be irritated to cause a red and scaly feeling.
The aloe vera, more specifically aloe vera 100:1, has a problem of weak skin elasticity and skin regeneration effect when it is contained in an amount of less than 0.1 wt% relative to the whole weight, and diarrhea, abdominal pain, nausea, vomiting and electrolyte disturbance may occur when it exceeds 1.5 wt%.
When the ginkgo biloba extract is contained in an amount of less than 0.1 wt% based on the total weight, the effects of improving blood circulation and preventing aging are weak, and when the content is more than 1.5 wt%, problems such as vomiting, diarrhea, fever and abdominal pain may occur.
When the content of the angelica extract is less than 0.1 wt% based on the total weight, the skin elasticity-strengthening and skin regeneration-promoting effects are weak, and when the content exceeds 1.5 wt%, diarrhea and fever may occur.
When the centella asiatica extract is contained in an amount of less than 0.1 wt% based on the total weight, the effect of soothing sensitive skin is weak, and when the content exceeds 1.5 wt%, itching and swelling of skin occur.
The chitosan and the saccharomyces cerevisiae may respectively comprise 0.1 to 1.5 wt% with respect to the total weight, preferably, the chitosan may comprise 0.5 to 1 wt%, and the saccharomyces cerevisiae may comprise 0.5 to 1 wt%, but not limited to the examples.
When the chitosan is contained in an amount of less than 0.1 wt% based on the total weight, there is a problem that the antibacterial effect and the moisturizing effect are weak, and when it exceeds 1.5 wt%, skin irritation is generated.
When the black yeast is contained in an amount of less than 0.1 wt% based on the total weight, there is a problem that the moisturizing and skin elasticity effects are weak, and when it exceeds 1.5 wt%, skin irritation occurs.
More preferably, the chitosan and the black yeast may be included at a weight ratio of 1:1 to 1:3, and when used within the range, the antibacterial, moisturizing and skin elasticity enhancing effects are improved, and when used below the range, the antibacterial and moisturizing enhancing effects may be exhibited by including the chitosan and the black yeast, but the skin moisturizing effect is weak.
In addition, when the amount of the black yeast is contained in an amount exceeding the above range, skin irritation may occur.
The composition for a female cleanser containing propolis and a natural extract according to an embodiment of the present invention may be prepared by the steps of: step 1: pulverizing propolis, collagen peptide and a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract and mixtures thereof to prepare a pulverized product; a 2 nd step of putting the pulverized material into a 20 to 50 mesh sieve to sieve it to prepare a first mixture; step 3, putting the excipient, the water-soluble vitamin, the disintegrant and the lubricant into a sieve with 20 to 50 meshes to sieve so as to prepare a second mixture; a 4 th step of adding the second mixture to the first mixture and mixing to prepare a third mixture; and 5, adding a lubricant into the third mixture obtained in the 4 step, mixing and tabletting.
More specifically, the 1 st step may pulverize propolis, collagen peptide, and a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract, and a mixture thereof using a blender to prepare a pulverized material.
The natural extract comprises a mixture of allantoin, aloe vera, ginkgo biloba extract, angelica extract and centella asiatica extract, and the natural extract may be in the form of a powder.
After the pulverized material is prepared in the 1 st step, the pulverized material may be put into a 20 to 50 mesh sieve to be sieved in the 2 nd step to prepare a first mixture. In more detail, the first mixture may be prepared by sieving the mixture in a 30 mesh sieve.
After the 2 nd step, in the 3 rd step, the excipient, the water-soluble vitamin, the disintegrant, and the lubricant are put into a 20 to 50 mesh sieve to be sieved to prepare a second mixture, and the second mixture prepared in the 3 rd step may be put into the first mixture of the 2 nd step to be mixed to prepare a third mixture.
A lubricant is added to the third mixture and mixed to prepare a composition for a female cleanser containing propolis and a natural extract according to an embodiment of the present invention.
The composition is for preventing or treating vaginal-related diseases, which are vaginal relaxation, vaginal dryness or vaginitis, and has excellent effects of inhibiting vaginal relaxation or vaginal dryness, demonstrating excellent effects of preventing or treating vaginitis, and vaginal-related diseases are not limited to the examples.
The composition is a cleaning composition or a vaginal tablet.
The present invention is a composition for a feminine cleanser, which may be a preparation for parenteral administration, and examples thereof include liquid preparations such as a liquid preparation, a gel (gel) preparation, a cleansing composition, a vaginal tablet, a suppository preparation, a cream preparation, an ointment, a dressing solution, a spray, a topical preparation such as other coating agents, a solution preparation, a suspension preparation, and an emulsion preparation, and skin external preparations such as a sterilized aqueous solution, a nonaqueous solvent, a suspension preparation, an emulsion preparation, a lyophilized preparation, a suppository, a cream, an ointment, a jelly, a foam, a detergent, and a vaginal insert, preferably a liquid preparation, a gel (gel) preparation, a cleansing composition, and a vaginal tablet.
For example, the formulation can be prepared by adding a solubilizing agent, an emulsifier, a buffer for adjusting pH, and the like to sterilized water. The non-aqueous solvent or suspending agent may be a vegetable oil such as propylene glycol (propylene glycol), polyethylene glycol (polyethylene glycol), olive oil, etc., an injectable ester such as ethyl oleate, etc.
The suppository can be witepsol, polyethylene glycol, tween 61(tween 61), cacao butter, lauric acid fat, glycerogelatin, etc. More specifically, the composition for a female cleanser may include a carrier added to the antibacterial composition to formulate the same. The carrier may use a binder, a lubricant, a suspending agent, a solubilizer, a buffer, a preservative, a lubricant, an isotonic agent, a stabilizer, a dispersing agent, a suspending agent, a pigment, a perfume, etc.
The preferred dose of the composition for a feminine cleanser according to one embodiment of the present invention varies depending on the state and body weight of the patient, the degree of disease, the form of the drug, the route and period of administration, but can be appropriately selected by a person skilled in the art.
The dosage of the composition for a female cleanser according to one embodiment of the present invention may be appropriately selected by a person skilled in the art in consideration of the administration method, the age, sex, and weight of the subject, and the severity of the disease. As an example, the amount of the pharmaceutical composition may be 0.0001mg/kg to 1000mg/kg, or more effectively, 0.01mg/kg to 100 mg/kg. For administration, the administration may be once a day, or may be performed in several times. The amount administered does not limit the scope of the invention in any way.
In addition, the composition for a female cleanser according to one embodiment of the present invention may include a compound having a known vaginal relaxation or vaginal dryness inhibitory activity, a compound having a vaginitis inhibitory activity, or a natural extract, in addition to the antibacterial composition.
The composition for female cleanser of one embodiment of the present invention can be directly applied to animals including human. The animal is a vertebrate, more particularly a mammal, which is ingested mainly with organic substances as nutrients and has a function of digestion or excretion and respiratory organ differentiation, corresponding to the biological group of plants. The mammal may be a human in detail.
Effects of the invention
The composition for a female cleanser containing propolis and a natural extract according to the present invention has an excellent effect of preventing or treating vaginal-related diseases.
The propolis composition contains propolis and natural extracts, has excellent effects on preventing or treating lax vagina, vaginal dryness or vaginitis, hardly causes irritation in use, is composed of natural substances, and is safe to use.
Drawings
Fig. 1 is a flow chart of a method of making a feminine cleanser composition in accordance with one embodiment of the invention.
Fig. 2 is a photograph showing pH results of a test after dissolving the composition for a female cleanser according to one embodiment of the present invention in purified water.
Detailed Description
Hereinafter, examples of the present invention will be described in detail so that those skilled in the art to which the present invention pertains can easily carry out the present invention. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[ preparation example: preparation of composition for female cleanser ]
1. Preparation of composition for female cleanser
0.3 wt% of collagen peptide, 0.3 wt% of allantoin, 0.3 wt% of aloe barbadensis 100:1, 0.3 wt% of ginkgo leaf extract, 0.3 wt% of angelica sinensis extract, 0.3 wt% of centella asiatica extract, and 0.89 wt% of propolis were pulverized with a blender and sieved with a 30-mesh sieve to prepare a first mixture.
Thereafter, 25.56% by weight of
20.77% by weight of Starch1500, 14.84% by weight of microcrystalline cellulose PH102, 29.67% by weight of mannitol 160C, 1.13% by weight of ascorbic acid, and 4.45% by weight of crospovidone CL-SF were placed in a 30 mesh sieve and sieved to prepare a second mixture, and the first and second mixtures were mixed, 0.89% by weight of magnesium stearate was placed, mixed, and tableted to prepare the composition for a feminine cleanser of test number IV 2.
More specific contents of the compositions for female cleanser of experiment numbers IV1, IV3 to 10 are as shown in table 1 below, prepared by adjusting the contents of excipients.
[ TABLE 1 ]
(unit: wt%)
2. Preparation of composition for female cleanser
A composition for a female cleanser was prepared with the same contents of ingredients and preparation method as in experiment No. IV2, except that chitosan and black yeast were further added.
The contents of the more specific components are shown in table 2 below.
[ TABLE 2 ]
| Experiment number | Chitosan | Black yeast |
| IT 1 | 0.05 | 0.05 |
| IT 2 | 0.3 | 0.3 |
| IT 3 | 0.5 | 0.5 |
| IT 4 | 1 | 1 |
| IT 5 | 1.5 | 1.5 |
| IT 6 | 2 | 2 |
| IT 7 | 0.5 | 1.5 |
| IT 8 | 1 | 2 |
| IT 9 | 0.05 | 0.5 |
(unit: wt%)
[ Experimental example 1: itch reducing Effect test
Women of 20-40 years old who experienced 80 persons who felt itching were selected and divided into 16 groups of 5 persons each, and they were evaluated for the effect of preventing itching after 10 days using the female cleanser compositions of test numbers IV1 to 10 and IT1 to 9 diluted in water, and the results thereof are shown in table 3. The score is 10 to 1, and a higher score indicates a more excellent effect of preventing itching.
[ TABLE 3 ]
As shown in Table 2, it was confirmed that the itching reducing effect was excellent in IV1, IV2, IV3 and IV5 in which the contents of propolis and natural extracts were 1:1 to 1:5,
IT was also confirmed that IT1 to 6, which further contained chitosan and black yeast, had an excellent effect of reducing itching, and IT3, IT4, IT7 and IT8 showed the most excellent effect of reducing itching.
[ Experimental example 2: skin irritation test
For 16 groups identical to those of experimental example 1, a difference was made in questionnaire as to whether or not irritation was generated in addition to the anti-itching effect, and the results are shown in tables 4 and 5 below.
[ evaluation standards ]
Very good: no irritation at all
O: has little irritation
And (delta): slightly irritating, and avoiding application to sensitive mucosa
PIKHz: severe irritation and no use
[ TABLE 4 ]
| IV1 | IV2 | IV3 | IV4 | IV5 | IV6 | IV7 | IV8 | IV9 | IV10 | |
| #1 | ○ | ○ | ○ | △ | ○ | △ | △ | Х | Х | △ |
| #2 | ○ | ○ | ○ | ○ | ○ | Х | Х | Х | △ | Х |
| #3 | ○ | ○ | ○ | △ | ○ | Х | △ | Х | Х | Х |
| #4 | ○ | ○ | ○ | ○ | ○ | △ | △ | △ | Х | Х |
| #5 | △ | ○ | ◎ | ○ | ◎ | △ | Х | Х | Х | △ |
[ TABLE 5 ]
| IT1 | IT2 | IT3 | IT4 | IT5 | IT6 | IT7 | IT8 | IT9 | |
| #1 | ○ | ○ | ◎ | ○ | ○ | △ | ○ | ◎ | ○ |
| #2 | ○ | ○ | ◎ | ◎ | △ | △ | ◎ | ◎ | △ |
| #3 | △ | △ | ○ | ◎ | ○ | △ | ◎ | ○ | ○ |
| #4 | △ | △ | ○ | ◎ | △ | △ | ◎ | ○ | △ |
| #5 | △ | ○ | ◎ | ○ | △ | △ | ○ | ◎ | △ |
According to the tables 4 and 5, with respect to IV1 to 5, evaluation was made of almost no skin irritation, whereas IV6 and IV10 produced skin irritation.
The skin irritation was not seriously evaluated for IT1 to IT9 as a whole, and the most excellent evaluations were obtained for IT3, IT4, IT7 and IT 8.
[ Experimental example: evaluation of cleaning ability
The same 16 groups as in experimental example 1 were investigated on the cleansing power, cleansing feeling, and fragrance when used as a female cleanser in addition to the anti-itch effect, and the results are shown in tables 6 and 7 below.
The score is 10 to 1, and a higher score indicates more excellent cleaning power, feeling of cleanliness, flavor, and overall preference.
[ TABLE 6 ]
| IV1 | IV2 | IV3 | IV4 | IV5 | IV6 | IV7 | IV8 | IV9 | IV10 | |
| Cleaning power | 6.8 | 8.4 | 8.0 | 6.8 | 8.0 | 5.2 | 3.6 | 6.0 | 5.4 | 6.0 |
| Sense of cleanliness | 6.4 | 8.2 | 7.8 | 6.2 | 8.2 | 5.8 | 3.2 | 5.8 | 5.6 | 5.4 |
| Incense stick | 6.2 | 8.4 | 8.2 | 7.4 | 8.0 | 3.0 | 6.0 | 5.2 | 6.0 | 5.6 |
| General preference | 6.2 | 8.4 | 8.0 | 7 | 8.1 | 5 | 3.2 | 5.2 | 5.8 | 5.8 |
[ TABLE 7 ]
| IT1 | IT2 | IT3 | IT4 | IT5 | IT6 | IT7 | IT8 | IT9 | |
| Cleaning power | 7.8 | 8.0 | 9.0 | 8.8 | 8.0 | 7.2 | 8.8 | 9.0 | 8.1 |
| Sense of cleanliness | 7.4 | 8.2 | 8.8 | 9.2 | 7.6 | 6.8 | 9.2 | 8.8 | 7.5 |
| Fragrance | 7.2 | 8.4 | 8.2 | 8.4 | 7.4 | 7.2 | 8.5 | 8.5 | 7.5 |
| General preference | 7.2 | 8.2 | 8.8 | 9.0 | 8.0 | 7.0 | 8.9 | 8.9 | 7.9 |
From the above tables 6 and 7, IV1 to IV3 and IV5 were excellent in terms of cleansing power, cleansing feeling, fragrance and overall preference, and among them, IV2, IV3 and IV5 were the most excellent.
In addition, the composition for a female cleanser containing chitosan and black yeast was excellent as a whole, and particularly IT3, IT4, IT7 and IT8 were the most excellent.
[ Experimental example 4: evaluation of moisture-holding ability
The moisturizing effect of skin was evaluated by detecting the evaporation rate of skin moisture for the groups IT1 to IT9 of experimental example 1.
The subjects used the female cleanser composition of the invention every night (between 7 and 9 o' clock), adhered for 4 weeks, tested once a week for 4 weeks, and recorded their results.
The skin moisture evaporation rate was measured using a Tewamter TM300 and expressed as an average value, and the results are shown in Table 8.
[ TABLE 8 ]
From the experimental results, IT was confirmed that when the female cleansers of IT1 to IT9 of the present invention were used, the moisture evaporation rate was reduced as a whole, and the skin moisturizing effect was exhibited.
The possibility of providing the composition as a female cleanser was confirmed, and the composition for a female cleanser of the present invention has an excellent effect of reducing itching and an excellent cleansing effect, and also has less skin irritation and an excellent skin moisturizing effect, unlike conventional female cleansers.
While the preferred embodiments of the present invention have been described in detail, the scope of the invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention defined in the claims are included in the scope of the invention.
Claims (10)
1. A composition for a feminine cleanser comprising propolis and a natural extract, comprising:
propolis;
a collagen peptide;
a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract, and mixtures thereof;
an excipient;
water-soluble vitamins;
a disintegrant; and
and (3) a lubricant.
2. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
comprises the propolis and the natural extract in a weight ratio of 1:1 to 1: 5.
3. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
said water-soluble vitamin is selected from vitamin C and vitamin B1Vitamin B2Nicotinic acid, vitamin B6Vitamin B12Folic acid and biotin.
4. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
the excipient is selected from the group consisting of silicified microcrystalline cellulose, starch, microcrystalline cellulose, mannitol, lactose, low substituted hydroxypropyl cellulose, sucralose, and mixtures thereof.
5. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
the disintegrant is selected from the group consisting of crospovidone, sodium starch gluconate, croscarmellose sodium, polysorbate, sodium lauryl sulfate, and mixtures thereof.
6. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
the lubricant is selected from the group consisting of magnesium stearate, light anhydrous silicic acid, talc, glyceryl behenate and mixtures thereof.
7. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
the composition is used for preventing or treating vagina related diseases,
the vagina related diseases comprise vaginal relaxation, vaginal dryness or vaginitis.
8. The composition for a female cleanser containing propolis and natural extracts according to claim 1, wherein,
the composition is a cleaning composition or a vaginal tablet.
9. A method for preparing a composition for a feminine cleanser containing propolis and a natural extract, comprising:
1, pulverizing propolis, collagen peptide and a natural extract selected from the group consisting of allantoin, aloe vera, ginkgo biloba extract, angelica extract, centella asiatica extract and mixtures thereof to prepare a pulverized product;
2, putting the crushed material into a 20-50 mesh sieve for sieving to prepare a first mixture;
step 3, putting the excipient, the water-soluble vitamin, the disintegrant and the lubricant into a sieve with 20 to 50 meshes to sieve so as to prepare a second mixture;
a 4 step of adding the second mixture to the first mixture and mixing to prepare a third mixture; and
and 5, adding a lubricant into the third mixture obtained in the 4 step, mixing and tabletting.
10. The method for preparing a composition for a feminine cleanser containing propolis and natural extracts as claimed in claim 9, wherein,
the first mixture of step 1 comprises propolis and a natural extract in a weight ratio of 1:1 to 1: 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010200440.7A CN113491765A (en) | 2020-03-20 | 2020-03-20 | Composition containing propolis and natural extract for female cleanser and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010200440.7A CN113491765A (en) | 2020-03-20 | 2020-03-20 | Composition containing propolis and natural extract for female cleanser and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113491765A true CN113491765A (en) | 2021-10-12 |
Family
ID=77993655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010200440.7A Pending CN113491765A (en) | 2020-03-20 | 2020-03-20 | Composition containing propolis and natural extract for female cleanser and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113491765A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152135A (en) * | 2007-08-30 | 2008-04-02 | 程贵昌 | Natural cleaning agent for human body reproductive organ |
| CN107456509A (en) * | 2017-08-30 | 2017-12-12 | 海南鸿昇生物药械有限公司 | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation |
| CN107982521A (en) * | 2017-12-13 | 2018-05-04 | 罗强 | A kind of women detergent and preparation method |
| CN108452295A (en) * | 2018-03-28 | 2018-08-28 | 丹东欣时代生物医药科技有限公司 | A kind of compact gel and preparation method antibacterial, that adjust microecological balance |
| KR101951733B1 (en) * | 2017-10-11 | 2019-02-25 | (주)인벤티지랩 | Cleansing composition for women's vagina comprising propolis and natural extracts and method for manufacturing the same |
| KR102020744B1 (en) * | 2019-03-13 | 2019-09-11 | 박시은 | Cleanser for women vagina using herb extract and method for manufacturing the same |
| CN110354224A (en) * | 2018-04-09 | 2019-10-22 | 韩术根 | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa, antipruritic, taste of dispelling |
| CN110478477A (en) * | 2019-09-20 | 2019-11-22 | 王其兵 | A kind of traditional Chinese biological preparation and preparation method thereof promoting female reproductive health |
| KR102071600B1 (en) * | 2019-06-07 | 2020-01-30 | 주식회사 메디셀 | Cream composition manufacturing method for preventing of sensitive-skin and skin-trouble |
-
2020
- 2020-03-20 CN CN202010200440.7A patent/CN113491765A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101152135A (en) * | 2007-08-30 | 2008-04-02 | 程贵昌 | Natural cleaning agent for human body reproductive organ |
| CN107456509A (en) * | 2017-08-30 | 2017-12-12 | 海南鸿昇生物药械有限公司 | A kind of external application biological agent and preparation method for vagina prevention, health care and treatment gynaecology genital inflammation |
| KR101951733B1 (en) * | 2017-10-11 | 2019-02-25 | (주)인벤티지랩 | Cleansing composition for women's vagina comprising propolis and natural extracts and method for manufacturing the same |
| CN107982521A (en) * | 2017-12-13 | 2018-05-04 | 罗强 | A kind of women detergent and preparation method |
| CN108452295A (en) * | 2018-03-28 | 2018-08-28 | 丹东欣时代生物医药科技有限公司 | A kind of compact gel and preparation method antibacterial, that adjust microecological balance |
| CN110354224A (en) * | 2018-04-09 | 2019-10-22 | 韩术根 | A kind of Traditional Chinese medicine gel composition antibacterial for vaginal mucosa, antipruritic, taste of dispelling |
| KR102020744B1 (en) * | 2019-03-13 | 2019-09-11 | 박시은 | Cleanser for women vagina using herb extract and method for manufacturing the same |
| KR102071600B1 (en) * | 2019-06-07 | 2020-01-30 | 주식회사 메디셀 | Cream composition manufacturing method for preventing of sensitive-skin and skin-trouble |
| CN110478477A (en) * | 2019-09-20 | 2019-11-22 | 王其兵 | A kind of traditional Chinese biological preparation and preparation method thereof promoting female reproductive health |
Non-Patent Citations (1)
| Title |
|---|
| 段红波等: "中药治疗阴道病研究进展", 中国实验方剂学杂志, vol. 23, no. 19, pages 227 - 234 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101951733B1 (en) | Cleansing composition for women's vagina comprising propolis and natural extracts and method for manufacturing the same | |
| KR101345709B1 (en) | Antibacterial and antifungal composition and Ladies genital area cleanser composition comprising antibacterial and antifungal composition for preventing and treating vaginitis | |
| WO2008140200A1 (en) | External compositions for the skin | |
| US20130108599A1 (en) | Herbal Vaginal Compositions | |
| CN111202822A (en) | Gynecological external antibacterial spray and preparation method thereof | |
| CN110638727B (en) | Infant hip-protecting composition and preparation method and application thereof | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| KR20190014774A (en) | Atopic dermatitis remedy and method for producing the same | |
| CN110721095B (en) | Herbal oral bacteriostatic spray containing propolis and preparation method thereof | |
| CN114712440A (en) | Dai medicine composition for relieving senile cutaneous pruritus and preparation and application thereof | |
| KR100999870B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata Thub and Ulmus davidana var.Japonica as an active ingredient | |
| KR100894439B1 (en) | The composition for cosmetics having the prevention effect of atopy | |
| CN108379350A (en) | A kind of eczema ointment and preparation method thereof | |
| EP3134099B1 (en) | Anti-candida compositions and uses thereof | |
| CN111803567A (en) | Camellia oil antibacterial and anti-inflammatory gel and preparation method thereof | |
| KR20150033797A (en) | Pharmaceutical composition for prevention and treatment of atopic skin disease | |
| KR100991399B1 (en) | Pharmaceutical composition for the prevention and treatment of allergic skin diseases containing extract of Houttuynia Cordata, Centella asiatica, Plantago asiatica, Ulmus davidana var. Japonica and Morus alba L. as an active ingredient | |
| CN113616774B (en) | Antibacterial composition containing plant stem cells, maintenance antibacterial liquid and preparation method thereof | |
| CN112755143B (en) | Traditional Chinese medicine composition for treating eczema and application thereof | |
| CN113491765A (en) | Composition containing propolis and natural extract for female cleanser and preparation method thereof | |
| KR102224920B1 (en) | Cleansing composition for women's vagina comprising natural | |
| CN113662998A (en) | A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method | |
| WO2021006507A1 (en) | Method for preparing composition powder for feminine wash containing propolis and natural extract | |
| KR20210130870A (en) | Feminine cleanser containing salt and quercus infectoria oak gall extract | |
| KR20200120280A (en) | Cleanser composition women's vagina and method for manufacturing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |